Large gap with delayed quotes
|
Last quote
08/30/2025
-
02:00:00
|
Bid
08/29/2025 -
21:59:59
|
Bid Volume |
Ask
08/29/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
69.72
+0.135
(
+0.19% )
|
69.71
|
2,000 |
69.78
|
900 |
Analysis date: 29.08.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 29.08.2025.
Interest
Weak
Weak
Two stars since 15.08.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 15.07.2025 at a price of 71.41.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 08.08.2025.
4wk Rel Perf
0.83%
0.83%
The four-week dividend-adjusted performance versus SP500 is .
Sensibility
High
High
The stock has been on the high-sensitivity level since 29.08.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.01%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.32%.
Mkt Cap in $bn
7.35
7.35
With a market capitalization between $2 & $8bn, CORCEPT THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
7.01
7.01
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
6.37
6.37
The estimated PE is for the year 2029.
LT Growth
44.67%
44.67%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
3
3
Over the last seven weeks, an average of 3 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
141
141
For 1% of index variation, the stock varies on average by 1.41%.
Correlation
0.32
0.32
Stock movements are strongly independent of index variations.
Value at Risk
24.16
24.16
The value at risk is estimated at USD 24.16. The risk is therefore 34.65%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025